Founding Date
Number of Shares
Capital
Number of EmployeesJanuary, Imuldosa(DMB-3115), Stelara® Biosimilar for Psoriasis, Launched Globally by Accord and Meiji
May, Held Global EVO Day with participation from Eurofarma, Cosma Medical, Metro Pharma Phils Inc., Berko Pharma, and Nairoukh Pharma
January, XCOPRI®(Cenobamate) License Agreement Signed for 30 Countries
November, Dystalis®(Motilitone), Launched in Mexico by EUROFARMA
October, Evogliptin and Udenafil, MEA Expansion Deal Signed with Jordanian Partner
August, Suganon®, Launched in Thailand by COSMA MEDICAL & in the Philippines by MPPI
April, Stillen & Motilitone, Signed Distributorship Agreement in the Philippines
November: Signed a license-out agreement for second-generation anemia biosimilar drug,
Darbepoetin alfa (DA-3880)with Polifarma in Turkey, covering Turkey, Brazil, and Mexico.
February, Suganon® Launched in Brazil by EUROFARMA
August: Entered a license-out agreement for multi-drug-resistant Gram-negative bacterial antibiotic, DA-7310,
with Yangtze River Pharmaceutical Group in China, covering China, Hong Kong, and Macau
July: a global license-out agreement (excluding Korea, Japan, and some Asian markets) for the biosimilar to Stelara,
DMB-3115, with multinational company Intas Pharmaceuticals
March: Relocated the Biotech Research Center to Songdo, Incheon
December: Recognized as a 2020 Family-Friendly Certified company, reflecting our employee-centric culture
December: Our growth hormone product, Grotropin, surpassed KRW 30 billion in annual sales
December: Launched Sugamet XR Tab. 5/1,000mg, expanding our diabetes treatment portfolio.
November: Signed an agreement with China's Hansoh Pharma to introduce a groundbreaking immuno-oncology drug
November: Hosted a Peace Forest Reforestation ceremony, symbolizing our dedication to social responsibility
October: Jublia, our nail fungus treatment, achieved over KRW 50 billion in cumulative sales
June: Passed the ISO 37001 anti-bribery management system for the second consecutive year, highlighting our ethical business practices
June: Established the Social Value Committee, demonstrating our commitment to sustainable management
June: Signed an agreement with the Korea Medical Assistance Foundation to provide medication support for low-income cancer patients
May: Results of Suganon EVERGREEN Study published in a prestigious SCI-level international journal
March: Successfully launched diabetes treatment Suganon in the Russian market
